Literature DB >> 18941225

Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.

Fumihiko Yasui1, Chieko Kai, Masahiro Kitabatake, Shingo Inoue, Misako Yoneda, Shoji Yokochi, Ryoichi Kase, Satoshi Sekiguchi, Kouichi Morita, Tsunekazu Hishima, Hidenori Suzuki, Katsuo Karamatsu, Yasuhiro Yasutomi, Hisatoshi Shida, Minoru Kidokoro, Kyosuke Mizuno, Kouji Matsushima, Michinori Kohara.   

Abstract

The details of the mechanism by which severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia are unclear. We investigated the immune responses and pathologies of SARS-CoV-infected BALB/c mice that were immunized intradermally with recombinant vaccinia virus (VV) that expressed either the SARS-CoV spike (S) protein (LC16m8rVV-S) or simultaneously all the structural proteins, including the nucleocapsid (N), membrane (M), envelope (E), and S proteins (LC16m8rVV-NMES) 7-8 wk before intranasal SARS-CoV infection. The LC16m8rVV-NMES-immunized group exhibited as severe pneumonia as the control groups, although LC16m8rVV-NMES significantly decreased the pulmonary SARS-CoV titer to the same extent as LC16m8rVV-S. To identify the cause of the exacerbated pneumonia, BALB/c mice were immunized with recombinant VV that expressed the individual structural proteins of SARS-CoV (LC16mOrVV-N, -M, -E, -S) with or without LC16mOrVV-S (i.e., LC16mOrVV-N, LC16mOrVV-M, LC16mOrVV-E, or LC16mOrVV-S alone or LC16mOrVV-N + LC16mOrVV-S, LC16mOrVV-M + LC16mOrVV-S, or LC16mOrVV-E + LC16mOrVV-S), and infected with SARS-CoV more than 4 wk later. Both LC16mOrVV-N-immunized mice and LC16mOrVV-N + LC16mOrVV-S-immunized mice exhibited severe pneumonia. Furthermore, LC16mOrVV-N-immunized mice upon infection exhibited significant up-regulation of both Th1 (IFN-gamma, IL-2) and Th2 (IL-4, IL-5) cytokines and down-regulation of anti-inflammatory cytokines (IL-10, TGF-beta), resulting in robust infiltration of neutrophils, eosinophils, and lymphocytes into the lung, as well as thickening of the alveolar epithelium. These results suggest that an excessive host immune response against the nucleocapsid protein of SARS-CoV is involved in severe pneumonia caused by SARS-CoV infection. These findings increase our understanding of the pathogenesis of SARS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941225     DOI: 10.4049/jimmunol.181.9.6337

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  121 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Authors:  Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge.

Authors:  Candice Clay; Nathan Donart; Ndingsa Fomukong; Jennifer B Knight; Wanli Lei; Lance Price; Fletcher Hahn; Jesse Van Westrienen; Kevin S Harrod
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Authors:  Yoshikazu Honda-Okubo; Dale Barnard; Chun Hao Ong; Bi-Hung Peng; Chien-Te Kent Tseng; Nikolai Petrovsky
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

5.  What We Need to Consider During and After the SARS-CoV-2 Pandemic.

Authors:  Willy A Valdivia-Granda; Jürgen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2020-05-29       Impact factor: 2.133

6.  Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.

Authors:  Jason Netland; Marta L DeDiego; Jincun Zhao; Craig Fett; Enrique Álvarez; José L Nieto-Torres; Luis Enjuanes; Stanley Perlman
Journal:  Virology       Date:  2010-01-27       Impact factor: 3.616

7.  Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.

Authors:  Craig Fett; Marta L DeDiego; Jose A Regla-Nava; Luis Enjuanes; Stanley Perlman
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

8.  Receptor-binding domain as a target for developing SARS vaccines.

Authors:  Xiaojie Zhu; Qi Liu; Lanying Du; Lu Lu; Shibo Jiang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 9.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Authors:  Wen Shi Lee; Adam K Wheatley; Stephen J Kent; Brandon J DeKosky
Journal:  Nat Microbiol       Date:  2020-09-09       Impact factor: 17.745

Review 10.  Respiratory viruses and eosinophils: exploring the connections.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.